2023
Predictors of Functional Impairment in Bipolar Disorder: Results From 13 Cohorts From Seven Countries by the Global Bipolar Cohort Collaborative
Burdick K, Millett C, Yocum A, Altimus C, Andreassen O, Aubin V, Belzeaux R, Berk M, Biernacka J, Blumberg H, Cleare A, Diaz-Byrd C, Dubertret C, Etain B, Eyler L, Forester B, Fullerton J, Frye M, Gard S, Godin O, Haffen E, Klaus F, Lagerberg T, Leboyer M, Martinez-Aran A, McElroy S, Mitchell P, Olie E, Olorunfemi P, Passerieux C, Peters A, Pham D, Polosan M, Potter J, Sajatovic M, Samalin L, Schwan R, Shanahan M, Solé B, Strawbridge R, Stuart A, Torres I, Ueland T, Vieta E, Williams L, Wrobel A, Yatham L, Young A, Nierenberg A, McInnis M. Predictors of Functional Impairment in Bipolar Disorder: Results From 13 Cohorts From Seven Countries by the Global Bipolar Cohort Collaborative. FOCUS The Journal Of Lifelong Learning In Psychiatry 2023, 21: 444-452. PMID: 38694997, PMCID: PMC11058953, DOI: 10.1176/appi.focus.23021021.Peer-Reviewed Original ResearchBipolar disorderFunctional impairmentComplete recoveryComorbid substance use disorderPersistent functional impairmentPatient's complete recoveryLogistic regression analysisPrior mood episodesProspective longitudinal studySubstance use disordersPsychotropic medicationsHeterogeneous presentationMood episodesClinical research communityDepressive symptomsOptimizing outcomesUse disordersCohortLower functioningLongitudinal studyRegression analysisGreater total numberHigh rateMultiple cohortsImpairment
2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez M, Honan E, Yang M, Chia P, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi M, Accordino M, Crew K, Hershman D, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer 2022, 4: 257-275. PMID: 36585452, PMCID: PMC9992270, DOI: 10.1038/s43018-022-00489-5.Peer-Reviewed Original ResearchConceptsBreast cancerDose-escalation clinical trialHDAC6 inhibitor ricolinostatMetastatic breast cancerPan-HDAC inhibitorsHistone deacetylaseHuman breast cancerIndividual histone deacetylaseSensitive cancer cellsNab-paclitaxelClinical responseMetastatic BCPredictive biomarkersClinical trialsClinical activityPreclinical studiesTumor typesHDAC6 activityCancer cellsHDAC6iAnticancer strategyPatientsRicolinostatCancerMultiple cohorts
2020
The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington S, Vercellino L, Zaucha J, Carvalho I, da Silva Maria G, Decazes P, Viailly P, Tilly H, Berriolo-Riedinger A, Casasnovas R, Hüttmann A, Ilyas H, Mikhaeel G, Dunn J, Cottereau A, Schmitz C, Paulson J, Nielsen T, Meignan M. The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136544.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaLarge B-cell lymphomaMetabolic tumor volumeProgression-free survivalB-cell lymphomaClinical trialsR-CHOPOverall survivalTumor volumeNewly diagnosed diffuse large B-cell lymphomaTotal metabolic tumor volumeStandard of careECOG PSCurative intentImmuno-chemotherapyPatientsMultiple centersEarly identificationCohortLymphomaTrialsSurvivalMultiple cohortsBaselineTMTV
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply